Supernus Pharmaceuticals (SUPN) Net Margin (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Net Margin data on file, last reported at 1.94% in Q4 2025.

• On a quarterly basis, Net Margin fell 1074.0% year-over-year to 1.94% in Q4 2025; TTM through Dec 2025 was 5.36%, a 1653.0% decrease from a year earlier, with the FY2025 full-year figure at 5.36%, down 1652.0% from the prior year.
• Net Margin for Q4 2025 stood at 1.94%, up from 23.49% in the prior quarter.
• Over the last five years, Net Margin for SUPN reached as high as 21.94% in Q3 2024 and fell as low as 23.49% in Q3 2025.
• Historically, Net Margin has averaged 4.93% across 5 years, with a median of 4.49% in 2022.
• Across the five-year window, Net Margin jumped 3232 bps in 2024 and tumbled 4542 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 1.54% in 2021, then surged by 893 bps to 15.24% in 2022, then sank by 95 bps to 0.72% in 2023, then surged by 1131 bps to 8.8% in 2024, then slumped by 122 bps to 1.94% in 2025.
• Per Business Quant data, the three most recent Net Margin figures were 1.94% in Q4 2025, 23.49% in Q3 2025, and 13.6% in Q2 2025.